Bayer Eylea (ophthalmology)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:drug
gptkbp:activeIngredient	gptkb:aflibercept
gptkbp:approvalYear	2011
gptkbp:approvedBy	gptkb:European_Medicines_Agency gptkb:U.S._Food_and_Drug_Administration
gptkbp:ATCCode	S01LA05
gptkbp:brand	gptkb:aflibercept
gptkbp:contraindication	active intraocular inflammation ocular infection
gptkbp:developedBy	gptkb:Regeneron_Pharmaceuticals
gptkbp:form	solution for injection
https://www.w3.org/2000/01/rdf-schema#label	Bayer Eylea (ophthalmology)
gptkbp:indication	gptkb:diabetic_macular_edema gptkb:neovascular_age-related_macular_degeneration macular edema following retinal vein occlusion myopic choroidal neovascularization
gptkbp:legalStatus	gptkb:drug
gptkbp:marketedAs	gptkb:Bayer gptkb:Santen_Pharmaceutical_(Japan) gptkb:Regeneron_Pharmaceuticals
gptkbp:marketingAuthorizationHolder	gptkb:Bayer
gptkbp:mechanismOfAction	VEGF inhibitor
gptkbp:prescriptionStatus	prescription only
gptkbp:routeOfAdministration	intravitreal injection
gptkbp:sideEffect	glaucoma conjunctival hemorrhage eye pain increased intraocular pressure vitreous detachment
gptkbp:therapeuticArea	ophthalmology
gptkbp:bfsParent	gptkb:Bayer
gptkbp:bfsLayer	5